Trial · NCT02051309
Guanfacine Clinical Trial for Smoking Cessation
NCT02051309, Phase 2, Completed, Yale University; results first posted 2021-12-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Guanfacine Clinical Trial for Smoking Cessation. Trials, record NCT02051309. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02051309
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Guanfacine Clinical Trial for Smoking Cessation
- NCT number
- NCT02051309
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 121 participants, actual
- Lead sponsor
- Yale University
- Conditions
- Smoking Cessation
- Interventions
- Guanfacine, Placebo
- First posted
- 2014-01-31
- Last updated
- 2021-12-29
- Results first posted
- 2021-12-29
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rates of Prolonged Smoking Abstinence | Week 3 to week 8 during 8-week treatment phase | Prolonged smoking abstinence defined as no relapse in week 3 to week 8, in participants with available outcome data during weeks 3 to 8. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Rates of Prolonged Smoking Abstinence | Week 3 to week 8 during 8-week treatment phase | Participants with available outcome data during weeks 3 to 8. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rates of Prolonged Smoking Abstinence | Guanfacine 6mg/Day ER | 11 | Participants | ||
| Rates of Prolonged Smoking Abstinence | Placebo | 7 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Guanfacine 6mg/Day ER | 58 | |
| Overall Study | STARTED | Placebo | 63 | |
| Overall Study | COMPLETED | Guanfacine 6mg/Day ER | 26 | |
| Overall Study | COMPLETED | Placebo | 35 | |
| Overall Study | NOT COMPLETED | Guanfacine 6mg/Day ER | 32 | |
| Overall Study | NOT COMPLETED | Placebo | 28 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Guanfacine 6mg/Day ER | 0 | 58 |
| Total, all-cause mortality | Placebo | 0 | 63 |
| Total, other adverse events | Guanfacine 6mg/Day ER | 0 | 58 |
| Total, other adverse events | Placebo | 0 | 63 |
| Total, serious adverse events | Guanfacine 6mg/Day ER | 0 | 58 |
| Total, serious adverse events | Placebo | 0 | 63 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DA035001 | Phase-II Clinical Trial Evaluating Guanfacine for Smoking Cessation | MCKEE, SHERRY ANN | YALE UNIVERSITY | NATIONAL INSTITUTE ON DRUG ABUSE | 2013 to 2015 |
Source NIH RePORTER
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Guanfacine 6mg/Day ER vs Placebo: deaths from any cause | Trial comparisons |
| Guanfacine 6mg/Day ER vs Placebo: Rates of Prolonged Smoking Abstinence | Trial comparisons |
| Guanfacine 6mg/Day ER vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02051309
GET https://conductscience.org/api/trials/v1/NCT02051309/registered